FGF19 Antibody (C-term)
- Known as:
- FGF19 Antibody (C-terminus)
- Catalog number:
- AP18231b
- Category:
- -
- Supplier:
- Abgen
- Gene target:
- FGF19 Antibody (C-term)
Related genes to: FGF19 Antibody (C-term)
- Gene:
- FGF19 NIH gene
- Name:
- fibroblast growth factor 19
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 11q13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1999-05-06
- Date modifiied:
- 2016-10-05
Related products to: FGF19 Antibody (C-term)
Related articles to: FGF19 Antibody (C-term)
- β-klotho (KLB), the obligate co-receptor for fibroblast growth factor (FGF) 19 and 21 signalling, has emerged as a therapeutic target for metabolic disease. Current understanding of KLB function is based largely on germline knockout mouse models, where developmental abnormalities obscure its function in adult physiology. Here, we used somatic hepatocyte-specific gene editing in adult mice to define hepatic KLB function. - Source: PubMed
Publication date: 2026/09/22
Aaldijk Alexandra SVerzijl Cristy R CHovingh Milaine VHuijkman Nicolette C ASmit MariekeKloosterhuis Niels JMulder Niels LHavinga RickGerding AlbertBos TrijnieKoster Mirjamde Graaf MariskaWolters Justina Cvan de Sluis BartStruik DickyJonker Johan W - The pregnane X receptor (Pxr; Nr1i2) plays a role in metabolic regulation. However, its contribution to systemic energy homeostasis under physiological conditions remains unclear. Here, we investigated the metabolic consequences of Nr1i2 deficiency in chow-fed mice. - Source: PubMed
Publication date: 2026/09/19
Benoit BérengèreJalabert AudreyMeugnier EmmanuelleChanon StéphanieVieille-Marchiset AurélieBeau AlicePesenti SandraLoizon EmmanuelleVitalis OrianeBendridi NadiaNawrot MargauxMakki KassemLe Magueresse-Battistoni BrigitteRieusset JenniferMichalski Marie-CarolineRainteau DominiqueChikh KarimVidal HubertRuzzin Jérôme - Oral cavity squamous cell carcinoma (OCSCC) is a common epithelial malignancy for which site-specific biomarkers with proven prognostic utility remain limited. In this study, we present one of the largest single-center, site-specific molecular analyses of OCSCC to date. Using two separate versions of multigene next-generation sequencing (NGS), we sought to identify a focused set of clinically actionable and widely accessible biomarkers that could support diagnosis, prognostication, and therapeutic decision-making. Our findings highlight the potential of a limited molecular panel to capture key prognostic information, supporting a more accessible and scalable approach to precision oncology in OCSCC. - Source: PubMed
Publication date: 2026/09/18
Afkhami MichelleHaghighi NMa HReyes AFei FDyer TTelatar MArias-Romero JHaghighi YMehrazma AMassarelli EBakkar RTizro PBell DVillaflor V M - Hepatocellular carcinoma (HCC) is the predominant histological subtype of primary liver cancer and remains a leading cause of cancer-related mortality because of its molecular heterogeneity, high recurrence rate, and incomplete responses to systemic therapy. Among dysregulated oncogenic networks, fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling contributes to hepatocarcinogenesis, angiogenesis, stromal remodeling, immune escape, and therapeutic resistance. This review critically examines the biological organization and translational implications of FGF/FGFR signaling in HCC, with particular emphasis on the FGF19-KLB-FGFR4 axis and a cautious appraisal of its current translational maturity. FGF2, the FGF8 subfamily, FGF9, and FGF19 drive context-dependent tumor programs shaped by etiology, cirrhosis, stromal interactions, intratumoral heterogeneity, and crosstalk with major oncogenic pathways. Although FGF19-KLB-FGFR4 is the most mature and clinically testable FGF-related therapeutic framework in HCC, selective FGFR4 inhibition is still limited by early-phase clinical evidence, bile-acid-related toxicity, FGFR3/KLB-mediated redundancy, bypass signaling, and acquired resistance. Early clinical data with irpagratinib support the rationale for combining FGFR4 inhibition with immune checkpoint blockade, but definitive validation and reproducible biomarker assays are still needed. Future translation should prioritize prospectively validated biomarker panels, mechanism-based combinations, longitudinal resistance monitoring, and models that recapitulate the cirrhotic, immune-active liver microenvironment. - Source: PubMed
Publication date: 2026/09/17
Jin QiangliLiu YangJin Penghui - This study investigated the effects of graded dietary barley replacement for corn on growth performance, rumen fermentation, carcass traits, meat quality, fatty acid profiles, and the rumen microbiome in Arbas White Cashmere goats, and further applied untargeted muscle metabolomics to elucidate the metabolic mechanisms underlying meat quality alterations. Growth performance was monitored for all goats (n = 10 per group); rumen fermentation, carcass traits, serum biochemistry and meat quality were determined in six randomly selected goats per group (n = 6); and rumen microbiota profiling and muscle metabolomics were performed on three selected goats per group (n = 3). Partial barley substitution (33% and 67% of starch from barley) significantly improved final body weight and average daily gain ( < 0.05), whereas total replacement (100% barley starch) did not confer additional growth advantages. Moderate barley inclusion increased ruminal propionate concentration ( = 0.001) and enriched the fiber-degrading bacterium Prevotella, while total barley replacement markedly reduced rumen microbial diversity (Sobs, Chao1, ACE, and Shannon indices; < 0.01) and depleted multiple fibrolytic and hydrogenotrophic genera, including , , and . The 33% barley group exhibited elevated serum total bile acids, FGF-19, and CYP27A1 levels ( < 0.05), suggestive of modulated bile acid metabolism, along with decreased glucose-6-phosphatase ( < 0.05), pointing to suppressed hepatic gluconeogenesis. Muscle metabolomics revealed that moderate barley substitution predominantly affected glycerophospholipid metabolism, with upregulation of PE(P-18:1/20:4) and PC(16:0/16:0), whereas total replacement induced extensive metabolic reprogramming characterized by downregulation of glycine and glutathione-related metabolites, indicative of compromised antioxidant defense. The 33% barley group also exhibited the highest muscular C18:3n-3 content ( < 0.01), while the 67% and total replacement groups showed increased C22:6n-3 deposition ( < 0.05). Correlation analysis confirmed that PE(P-18:1/20:4) and PC(16:0/16:0) were significantly positively correlated with ruminal propionate and ADG (r = 0.841-0.986; < 0.05), and Prevotella abundance showed a strong negative trend with G-6-Pase (r = -0.771). Collectively, these findings demonstrate that replacing one-third of dietary corn starch with barley starch optimally balances productivity, rumen health, and meat quality through enrichment of Prevotella, enhanced propionate production, and modulation of bile acid metabolism, while excessive barley inclusion destabilizes the rumen ecosystem and triggers muscle oxidative stress, providing a theoretical basis for precision grain formulation in intensive cashmere goat production. - Source: PubMed
Publication date: 2026/09/06
Jin LuZhang ChunhuaLi ShengliSa ChulaNuo MinYang DingLi WentingFu LeChen PanliangZhao YaxingWang BoSun Haizhou